MB, Levis & Associates’s AbbVie ABBV Stock Holding History

MB, Levis & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$119K	Hold	547	–	–	0.05%	71
2025 Q4	$125K	Hold	547	–	–	0.05%	72
2025 Q3	$127K	Hold	547	–	–	0.05%	71
2025 Q2	$102K	Hold	547	–	–	0.04%	88
2025 Q1	$115K	Hold	547	–	–	0.05%	80
2024 Q4	$97.2K	Hold	547	–	–	0.05%	86
2024 Q3	$108K	Hold	547	–	–	0.05%	79
2024 Q2	$93.8K	Hold	547	–	–	0.05%	84
2024 Q1	$99.6K	Buy	547 +4	+0.7%	+$689	0.05%	85
2023 Q4	$84.2K	Buy	543 +4	+0.7%	+$583	0.05%	88
2023 Q3	$80.3K	Buy	539 +4	+0.7%	+$587	0.05%	91
2023 Q2	$72K	Buy	535 +6	+1%	+$880	0.05%	94
2023 Q1	$84.4K	Buy	529 +5	+1%	+$764	0.06%	88
2022 Q4	$84.7K	Buy	+524	New	+$80.3K	0.07%	82

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MB, Levis & Associates's ABBV Position: Q1 2026 in Review

MB, Levis & Associates held its AbbVie (ABBV) position steady in Q1 2026 at 547 shares worth $119K. The position accounts for 0.05% of the portfolio, ranked #71.

MB, Levis & Associates first reported a position in ABBV in Q4 2022 and has held it in 14 quarters since. The position peaked at $127K in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

MB, Levis & Associates held 547 shares of AbbVie worth $119K as of Q1 2026.
MB, Levis & Associates left its AbbVie share count unchanged in Q1 2026.
AbbVie made up 0.05% of MB, Levis & Associates's portfolio in Q1 2026, its #71 holding.
MB, Levis & Associates first reported a position in AbbVie in Q4 2022 and has held it in 14 quarters since.
MB, Levis & Associates's AbbVie position peaked at $127K in Q3 2025.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on MB, Levis & Associates's 13F filing for Q1 2026, filed 8 Apr 2026.